Mersana Therapeutics Stock Price, News & Analysis (NASDAQ:MRSN)

$16.07 +1.37 (+9.32 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$16.07
Today's Range$13.72 - $16.85
52-Week Range$12.45 - $21.01
Volume161,800 shs
Average Volume88,403 shs
Market Capitalization$334.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics logoMersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020

Debt

Debt-to-Equity RatioN/A
Current Ratio5.58%
Quick Ratio5.58%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees68
Outstanding Shares22,750,000

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.14. The business earned $6.27 million during the quarter, compared to analysts' expectations of $3.93 million. View Mersana Therapeutics' Earnings History.

Where is Mersana Therapeutics' stock going? Where will Mersana Therapeutics' stock price be in 2018?

5 analysts have issued 12-month price objectives for Mersana Therapeutics' stock. Their forecasts range from $23.00 to $25.00. On average, they anticipate Mersana Therapeutics' stock price to reach $23.67 in the next twelve months. View Analyst Ratings for Mersana Therapeutics.

Who are some of Mersana Therapeutics' key competitors?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the folowing people:

  • David M. Mott, Chairman of the Board (Age 51)
  • Anna Protopapas, President, Chief Executive Officer, Director (Age 52)
  • Timothy B. Lowinger Ph.D., Chief Scientific Officer
  • Wayne Foster CPA, Vice President - Finance
  • Donald A. Bergstrom M.D. Ph.D., Chief Medical Officer
  • Lawrence M. Alleva, Independent Director (Age 67)

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Mersana Therapeutics stock?

Mersana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (3.96%), BlackRock Inc. (2.54%), Geode Capital Management LLC (0.28%), Victory Capital Management Inc. (0.25%), Goldman Sachs Group Inc. (0.07%) and Spark Investment Management LLC (0.06%). View Institutional Ownership Trends for Mersana Therapeutics.

Who sold Mersana Therapeutics stock? Who is selling Mersana Therapeutics stock?

Mersana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. View Insider Buying and Selling for Mersana Therapeutics.

Who bought Mersana Therapeutics stock? Who is buying Mersana Therapeutics stock?

Mersana Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, BlackRock Inc., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., TIAA CREF Investment Management LLC, Geode Capital Management LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Mersana Therapeutics.

How do I buy Mersana Therapeutics stock?

Shares of Mersana Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of Mersana Therapeutics stock can currently be purchased for approximately $16.07.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $334.48 million. Mersana Therapeutics employs 68 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]


MarketBeat Community Rating for Mersana Therapeutics (MRSN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  114
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mersana Therapeutics (NASDAQ:MRSN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.67$23.67$23.67$23.67
Price Target Upside: 54.48% upside68.45% upside68.45% upside68.45% upside

Mersana Therapeutics (NASDAQ:MRSN) Consensus Price Target History

Price Target History for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ:MRSN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018HC WainwrightInitiated CoverageBuyMediumView Rating Details
7/24/2017WedbushReiterated RatingOutperform -> Outperform$25.00HighView Rating Details
7/24/2017Leerink SwannInitiated CoverageOutperform -> Outperform$23.00HighView Rating Details
7/24/2017JPMorgan Chase & Co.Initiated CoverageOverweight -> Overweight$23.00HighView Rating Details
7/24/2017CowenInitiated CoverageOutperformHighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Mersana Therapeutics (NASDAQ:MRSN) Earnings History and Estimates Chart

Earnings by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ MRSN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.49)($0.35)$3.93 million$6.27 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.56)($6.33)$3.33 million$3.73 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mersana Therapeutics (NASDAQ:MRSN) Earnings Estimates

2018 EPS Consensus Estimate: ($8.72)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($2.33)($2.33)($2.33)
Q2 20181($2.26)($2.26)($2.26)
Q3 20181($2.46)($2.46)($2.46)
Q4 20181($1.67)($1.67)($1.67)
Q1 20191$9.82$9.82$9.82
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Mersana Therapeutics (NASDAQ:MRSN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mersana Therapeutics (NASDAQ MRSN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 73.63%
Insider Trades by Quarter for Mersana Therapeutics (NASDAQ:MRSN)
Institutional Ownership by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ MRSN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/3/2017M James BarrettMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mersana Therapeutics (NASDAQ MRSN) News Headlines

Source:
DateHeadline
$3.57 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter$3.57 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter
www.americanbankingnews.com - February 18 at 12:56 PM
HC Wainwright Initiates Coverage on Mersana Therapeutics (MRSN)HC Wainwright Initiates Coverage on Mersana Therapeutics (MRSN)
www.americanbankingnews.com - February 15 at 9:58 AM
Mersana Therapeutics to Present at Upcoming Investor ConferencesMersana Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:08 AM
Mersana Therapeutics (MRSN) Rating Increased to Sell at ValuEngineMersana Therapeutics (MRSN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 9:46 PM
Mersana Therapeutics Inc (MRSN) Given Consensus Rating of "Buy" by AnalystsMersana Therapeutics Inc (MRSN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 1:48 AM
Zacks: Analysts Set $23.67 Price Target for Mersana Therapeutics Inc (MRSN)Zacks: Analysts Set $23.67 Price Target for Mersana Therapeutics Inc (MRSN)
www.americanbankingnews.com - January 30 at 7:46 AM
Zacks: Analysts Anticipate Mersana Therapeutics Inc (MRSN) Will Post Earnings of -$0.51 Per ShareZacks: Analysts Anticipate Mersana Therapeutics Inc (MRSN) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - January 30 at 5:08 AM
$3.82 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter$3.82 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter
www.americanbankingnews.com - January 15 at 9:44 PM
 Brokerages Set $23.67 Target Price for Mersana Therapeutics Inc (MRSN) Brokerages Set $23.67 Target Price for Mersana Therapeutics Inc (MRSN)
www.americanbankingnews.com - January 15 at 5:38 PM
-$0.51 Earnings Per Share Expected for Mersana Therapeutics Inc (MRSN) This Quarter-$0.51 Earnings Per Share Expected for Mersana Therapeutics Inc (MRSN) This Quarter
www.americanbankingnews.com - January 13 at 7:52 AM
Mersana Therapeutics Outlines 2017 Milestones and 2018 GoalsMersana Therapeutics Outlines 2017 Milestones and 2018 Goals
finance.yahoo.com - January 8 at 12:04 PM
Zacks Investment Research Downgrades Mersana Therapeutics (MRSN) to SellZacks Investment Research Downgrades Mersana Therapeutics (MRSN) to Sell
www.americanbankingnews.com - January 3 at 11:54 AM
Mersana Therapeutics (MRSN) & Its Competitors Head-To-Head ReviewMersana Therapeutics (MRSN) & Its Competitors Head-To-Head Review
www.americanbankingnews.com - January 2 at 3:16 PM
Zacks: Mersana Therapeutics Inc (MRSN) Given $23.67 Consensus Target Price by AnalystsZacks: Mersana Therapeutics Inc (MRSN) Given $23.67 Consensus Target Price by Analysts
www.americanbankingnews.com - December 31 at 7:30 AM
Mersana Therapeutics (MRSN) vs. Its Peers Head to Head ReviewMersana Therapeutics (MRSN) vs. Its Peers Head to Head Review
www.americanbankingnews.com - December 31 at 1:32 AM
Mersana Therapeutics (MRSN) & The Competition Head-To-Head ContrastMersana Therapeutics (MRSN) & The Competition Head-To-Head Contrast
www.americanbankingnews.com - December 29 at 5:28 AM
Mersana Therapeutics, Inc. is trading above its 50 day moving average : MRSN-US : December 28, 2017Mersana Therapeutics, Inc. is trading above its 50 day moving average : MRSN-US : December 28, 2017
finance.yahoo.com - December 28 at 12:01 PM
Clovis Oncology (CLVS) vs. Mersana Therapeutics (MRSN) Financial ReviewClovis Oncology (CLVS) vs. Mersana Therapeutics (MRSN) Financial Review
www.americanbankingnews.com - December 22 at 7:27 PM
Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 5:45 PM
Mersana Therapeutics Incs Lock-Up Period Will End  on December 25th (NASDAQ:MRSN)Mersana Therapeutics Inc's Lock-Up Period Will End on December 25th (NASDAQ:MRSN)
www.americanbankingnews.com - December 18 at 1:14 AM
Mersana Therapeutics Added to NASDAQ Biotechnology IndexMersana Therapeutics Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 15 at 9:16 AM
Zacks: Brokerages Set $23.67 Price Target for Mersana Therapeutics Inc (MRSN)Zacks: Brokerages Set $23.67 Price Target for Mersana Therapeutics Inc (MRSN)
www.americanbankingnews.com - December 15 at 5:52 AM
Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing TumorsMersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors
finance.yahoo.com - December 12 at 9:25 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : December 7, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : December 7, 2017
finance.yahoo.com - December 7 at 9:00 AM
Mersana Therapeutics Inc (MRSN): Earnings Expected To Remain SubduedMersana Therapeutics Inc (MRSN): Earnings Expected To Remain Subdued
finance.yahoo.com - December 4 at 5:49 PM
Zacks: Brokerages Set $23.67 Target Price for Mersana Therapeutics, Inc. (MRSN)Zacks: Brokerages Set $23.67 Target Price for Mersana Therapeutics, Inc. (MRSN)
www.americanbankingnews.com - November 26 at 9:34 AM
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : November 24, 2017Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : November 24, 2017
finance.yahoo.com - November 24 at 6:42 PM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017
finance.yahoo.com - November 23 at 6:37 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 9, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 9, 2017
finance.yahoo.com - November 12 at 8:37 AM
Mersana Announces Third Quarter 2017 Financial Results and Provides Business UpdatesMersana Announces Third Quarter 2017 Financial Results and Provides Business Updates
finance.yahoo.com - November 12 at 8:37 AM
 Mersana Therapeutics, Inc. (MRSN) Receives Consensus Recommendation of "Strong Buy" from Analysts Mersana Therapeutics, Inc. (MRSN) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 11 at 11:46 PM
Mersana Therapeutics, Inc. (MRSN) Announces Quarterly  Earnings Results, Beats Expectations By $0.13 EPSMersana Therapeutics, Inc. (MRSN) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS
www.americanbankingnews.com - November 10 at 2:56 PM
Zacks: Mersana Therapeutics, Inc. (MRSN) Receives Average Rating of "Strong Buy" from AnalystsZacks: Mersana Therapeutics, Inc. (MRSN) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 7 at 10:59 AM
A requirement at this Cambridge biotech: Must love dogsA requirement at this Cambridge biotech: Must love dogs
finance.yahoo.com - November 2 at 6:34 AM
Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International ConferenceMersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference
finance.yahoo.com - October 31 at 6:30 AM
Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2bMersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
finance.yahoo.com - October 31 at 6:30 AM
Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsMersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 24 at 6:53 AM
 Mersana Therapeutics, Inc. (MRSN) Given $23.67 Average Target Price by Brokerages Mersana Therapeutics, Inc. (MRSN) Given $23.67 Average Target Price by Brokerages
www.americanbankingnews.com - October 23 at 10:58 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : October 16, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : October 16, 2017
finance.yahoo.com - October 17 at 12:17 AM
Boston biotech developing obesity drug pulls down $120M in IPOBoston biotech developing obesity drug pulls down $120M in IPO
finance.yahoo.com - October 5 at 9:17 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : September 20, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : September 20, 2017
finance.yahoo.com - September 22 at 6:07 AM
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : September 21, 2017Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : September 21, 2017
finance.yahoo.com - September 22 at 6:07 AM
 Mersana Therapeutics, Inc. (MRSN) Given $23.67 Consensus Target Price by Brokerages Mersana Therapeutics, Inc. (MRSN) Given $23.67 Consensus Target Price by Brokerages
www.americanbankingnews.com - September 7 at 4:44 AM
Mersana Therapeutics to Participate in Investor Conferences in SeptemberMersana Therapeutics to Participate in Investor Conferences in September
finance.yahoo.com - August 31 at 7:30 AM
 Mersana Therpts (MRSN) Given Consensus Recommendation of "" by Analysts Mersana Therpts (MRSN) Given Consensus Recommendation of "" by Analysts
www.americanbankingnews.com - August 17 at 12:38 PM
FY2017 EPS Estimates for Mersana Therpts (MRSN) Decreased by Leerink SwannFY2017 EPS Estimates for Mersana Therpts (MRSN) Decreased by Leerink Swann
www.americanbankingnews.com - August 17 at 9:00 AM
FY2018 Earnings Forecast for MERSANA THERPTS (MRSN) Issued By Leerink SwannFY2018 Earnings Forecast for MERSANA THERPTS (MRSN) Issued By Leerink Swann
www.americanbankingnews.com - August 16 at 1:32 PM
Mersana Therpts (NASDAQ:MRSN) Short Interest Down 95.9% in JulyMersana Therpts (NASDAQ:MRSN) Short Interest Down 95.9% in July
www.americanbankingnews.com - August 13 at 2:20 AM
Mersana Therpts (MRSN) Issues  Earnings Results, Misses Expectations By $5.77 EPSMersana Therpts (MRSN) Issues Earnings Results, Misses Expectations By $5.77 EPS
www.americanbankingnews.com - August 12 at 10:41 AM
Mersana Announces Second Quarter 2017 Financial Results and Provides Business UpdatesMersana Announces Second Quarter 2017 Financial Results and Provides Business Updates
finance.yahoo.com - August 12 at 5:53 AM

SEC Filings

Mersana Therapeutics (NASDAQ:MRSN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mersana Therapeutics (NASDAQ:MRSN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mersana Therapeutics (NASDAQ MRSN) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.